This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurogenetics  • Movement Disorders  • Neurology, Other  • Women's Health  • Women's Health, Other  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

The PHAROS (Prospective Huntington At Risk Observational Study) Cohort Enrolled

The Huntington Study Group PHAROS Investigators^*

Arch Neurol. 2006;63:991-996.

Objective  To identify the emerging clinical precursors that indicate the early onset of Huntington disease (HD) in a reliable and gene-specific manner. This information is critical for the development of therapeutic trials aimed at postponing clinical onset in HD gene carriers.

Methods  Between July 1999 and January 2004, 1001 adults at 50-50 risk for HD agreed to provide longitudinal clinical data and a blood DNA sample under consent provisions that require their individual clinical and genetic information to never be revealed.

Results  The Prospective Huntington At Risk Observational Study (PHAROS) cohort is characterized by a 2:1 predominance of women to men, high educational attainment, and gainful employment. Despite the gender disparity, the demographic, hereditary, and clinical characteristics of the female and male participants were similar. Investigators, who are unaware of individual gene status, characterized the baseline cohort to be highly functional with minimal motor or cognitive impairment; 92.3% of participants were judged to have no or nonspecific motor abnormalities; 6.7%, to have possible or probable motor signs; and only 1.0%, to have unequivocal HD.

Conclusion  The baseline characteristics of the PHAROS cohort make it well suited to generate objective and prospective data about gene-specific clinical precursors that can be used as outcomes in controlled trials aimed at postponing the onset of HD.

*Authors/Group Information: The authors and members of the Huntington Study Group PHAROS Investigators are listed on pages 997 and 998 in the printed journal.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dietary intake in adults at risk for Huntington disease: Analysis of PHAROS Research Participants
Marder et al.
Neurology 2009;73:385-392.
ABSTRACT | FULL TEXT  

Effects of an intensive rehabilitation programme on patients with Huntington's disease: a pilot study
Zinzi et al.
Clin Rehabil 2007;21:603-613.
ABSTRACT  

Juvenile-Onset Huntington Disease: A Matter of Perspective
Biglan and Shoulson
Arch Neurol 2007;64:783-784.
FULL TEXT  

Genetic testing in Parkinson disease: promises and pitfalls.
Tan and Jankovic
Arch Neurol 2006;63:1232-1237.
FULL TEXT  

The eyes as a window into disease prevention
Biglan and Halmagyi
Neurology 2006;67:376-377.
FULL TEXT